Clinical Trials
12 trialsNCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT04100694 2025-05-20
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus B.V.
Approved for marketing
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT05046444 2024-12-17
SIRIUS
Munich Leukemia Laboratory
Recruiting
NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
NCT03053466 2022-05-09
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
Apollomics (Australia) Pty. Ltd.
Phase 1 Completed
NCT03896958 2020-12-04
PIONEER
SpeciCare
Unknown
NCT03628079 2020-01-22
RepoMeb
Repos Pharma
Phase 1/2 Terminated
NCT02628379 2018-07-10
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
Foundation Medicine
Completed
NCT00873119 2015-07-28
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Valerio Therapeutics
Phase 2 Completed
NCT01202786 2012-08-15
Cost-effectiveness Study of miRviewâ„¢ Mets in Patients With Cancer of Unknown Primary (CUP)
Teva Branded Pharmaceutical Products R&D, Inc.
Completed